Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery for rare diseases, is taking more than 3,500 sq ft of space within the Park’s multi-occupancy lab building.
The Science Village is home to both established and start-up companies including leading bioscience ventures, so Healx will be in good company in this innovative, energy efficient building.
The fully fitted, high-quality suites are served by high-speed data connectivity, dedicated external plant area and Cat 6 cabling. These ready-made labs include demountable benching, an open plan write up area, plus a self-contained single office which means that Healx can ‘plug and play’ without needing to initiate an extensive fit out.
Focused on finding novel treatments for patients with rare diseases, Healx is deeply passionate about the application of AI to improve access to treatment and the new lab will allow the Healx team to accelerate the discovery and validation of potential new therapies for more rare conditions.
Dr Neil Thompson, Healx, Chief Scientific Officer, said: “Historically, we have worked through partnerships to access the experimental systems we require for our preclinical and clinical programmes, but, as our team and operations have scaled, we started looking to secure our own labs in order to support our growing portfolio of disease projects and to expand the proprietary data types we use in our AI platform.
“The Chesterford Research Park facility is ideal for us and will play a pivotal role in our vision for the next generation of drug discovery for rare diseases. The modern, purpose-built lab has the flexibility to support our scientific and technical ambitions and the location – close to our Cambridge headquarters – will enable us to expand our team with experienced local talent. Importantly, the Park Management staff have been very supportive in enabling a speedy acquisition, and we are looking forward to getting up and running in the space.”
Julian Cobourne, Head of Regional Offices, Aviva Investors, joint owners of Chesterford Research Park with Uttlesford District Council commented: “We are thrilled to provide space for a new breed of healthcare technology companies, like Healx, to grow amongst our existing community of cutting-edge, global life science companies. With its new lab space in the Park’s innovative community, Healx will be able to continue its crucial research, rapid expansion and recruitment.”
Chesterford Research Park provides a superb environment for innovative research and development for both established and early-stage biotechnology and pharmaceutical companies and is home to life science and technology innovators including Arecor, AstraZeneca, Cambridge Epigenetix, Charles River Laboratories, Domainex, Illumina and Lonza.
Park owners Aviva Investors and Uttlesford District Council are advised by Chesterford Research Park’s joint commercial agents, Savills and Cheffins and developer The Churchmanor Estates Company plc.